Opioid NMDA CYP2D6 Combination for Pain Relief
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pain treatment options, particularly opioid agonists, are limited by severe side effects and the development of tolerance, which reduces their effectiveness over time.
Innovation Solution
Pharmaceutical compositions combining an opioid agonist, a NMDA antagonist, and a CYP2D6 inhibitor, such as dextromethorphan, quinidine, and morphine, oxycodone, or hydromorphone, to enhance pain relief while minimizing side effects and delaying tolerance development.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If opioid agonists are used to treat pain, then pain relief is achieved, but severe side effects and tolerance development occur
Solution Approach 1:
The patent combines three distinct pharmacological agents into a single composition: an opioid agonist (for pain relief), an NMDA antagonist (to block pain signal transmission and reduce tolerance), and a CYP2D6 inhibitor (to modulate drug metabolism and enhance efficacy). This merging of multiple mechanisms of action allows the composition to achieve reliable pain relief while mitigating the harmful side effects and tolerance development associated with opioid agonists alone.
Solution Approach 2:
The invention creates a composite pharmaceutical composition where each component contributes a specific therapeutic function. The opioid agonist provides analgesia, the NMDA antagonist provides neuroprotective and analgesic effects while reducing opioid tolerance, and the CYP2D6 inhibitor modulates the metabolic pathway to enhance and prolong the therapeutic effect. This composite approach allows the formulation to overcome the limitations of single-agent therapy.
2Reliability
If higher doses of opioid agonists are used to overcome tolerance, then pain relief is maintained, but side effects increase
Solution Approach 1:
The patent fundamentally changes the pharmacological parameters of pain treatment by introducing two additional active components with different mechanisms of action. Instead of increasing the dose of opioid agonist alone, the composition uses the NMDA antagonist to block central pain processing pathways and the CYP2D6 inhibitor to modulate metabolic clearance, thereby maintaining pain relief effectiveness at lower opioid doses and reducing adverse reactions.
Solution Approach 2:
The NMDA antagonist and CYP2D6 inhibitor act as intermediary agents that enhance the overall therapeutic effect without requiring increased opioid agonist dosage. The NMDA antagonist mediates additional analgesic effects through a different neurobiological pathway, while the CYP2D6 inhibitor mediates prolonged drug action by blocking metabolic degradation, both serving as intermediaries that amplify pain relief while limiting opioid-related side effects.
Data Source
AI summary
Embodiments disclosed herein describe, amongst other things, dosage forms, compounds, compositions, pharmaceutical compositions that can be used in the treatment of, for example, pain and pain related disorders or to produce analgesia.